Eurofins to offer biopharma testing in Japan with Astellas lab deal

By Flora Southey contact

- Last updated on GMT

Getty/Laurent Watanabe
Getty/Laurent Watanabe
Astellas will contract out an internal testing laboratory to Eurofins Scientific, marking the CRO’s entry into biopharmaceutical product testing in Japan.

Contract research organisation (CRO) Eurofins has signed an outsourcing agreement with Japanese pharmaceutical company Astellas for one of its testing laboratories in Kyoto.

Astellas’ Analytical Science Laboratories (ASL) offers testing services for raw materials and drug substances, as well as quality evaluation, test method validation, and physicochemical testing.

The laboratory also tests cell based assay for antibodies, offering Eurofins entry into the biopharmaceutical products testing market in Japan.

According to the agreement, Astellas will provide ASL work for “an agreed period of time” ​while Eurofins invests in capabilities and adds staff to the current 140-member workforce.

Eurofins is committed to serving Astellas and its “expanding group of clients in the APAC region,” ​CEO Gilles Martin said in a statement.

The CRO declined a request for additional comment.

The Astellas deal marks Luxembourg-headquartered Eurofins’ latest expansion into the global market. In 2016, the CRO acquired US analytical services firm Advantar Laboratories​, Australian QC company ams​, and Dutch QC services firm Sinensis Life Science.

Last year, the firm bought Canadian drug ingredient manufacturer and testing contractor Alphora Research​ and India-based preclinical CRO Advinus Therapeutics​. And in January this year, Eurofins announced plans to buy UK CRO Selcia​.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars